Reported about 7 hours ago
Gilead Sciences and the U.S. government have reached a settlement in a billion-dollar patent case involving Gilead's HIV prevention drugs, Truvada and Descovy. This follows Gilead's victory in a 2023 jury trial where the government alleged patent infringement. The settlement allows Gilead to focus on developing therapeutics, despite claims from the government that Gilead undercompensated the CDC for their role in the drug's development.
Source: YAHOO